DIABETES CARE MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Diabetes Care Market, By Product Type (Glucose Monitoring Devices (Blood glucose monitoring (BGM), Continuous glucose monitoring (CGM), Flash glucose monitoring (FGM)), Insulin Pumps (Patch pump, Tethered pump, Implanted insulin pump, and Others (Insulin Syringes, Pen Needles, etc.)), By Diabetes Type (Type 2 Diabetes, Type 1 Diabetes, and Other (Gestational Diabetes, etc.)), By End User (Hospitals & Clinics, Homecare Settings, Ambulatory Care Settings, and Others (Academic and Research Institutes, Clinical Laboratories, etc.)), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

On September 5, 2024, Abbott, a global healthcare company, announced the launch of its over-the-counter continuous glucose monitoring system, Lingo, in the U.S. This innovative system allows consumers to track their glucose levels without a prescription, utilizing Abbott's advanced FreeStyle Libre technology. Lingo provides real-time glucose data and insights through a mobile app, empowering users to manage their health and wellness more effectively.
On August 26, 2024, Dexcom, Inc., a company that develops, manufactures, produces, and distributes continuous glucose monitoring (CGM) systems for diabetes management, announced the launch of Stelo, its first over-the-counter continuous glucose monitoring (CGM) system in the U.S. This innovative device is designed for individuals with Type 2 diabetes who do not use insulin and those with prediabetes.
In April 2023, Medtronic, a medical device company, announced that the U.S. Food and Drug Administration (FDA) approved its MiniMed 780G System, the world's first insulin pump featuring meal detection technology with five-minute auto corrections. This advanced hybrid closed-loop system is designed for individuals aged seven and older with Type 1 diabetes. It integrates the MiniMed pump with the Guardian 4 continuous glucose monitoring sensor to automatically adjust insulin delivery based on real-time glucose readings.